much, Fred. you very thank Well,
off an unmet X, principal refractory B-cell diffuse considered is profile is the to fill the for this gap. of dilemma easily accessible treatment many my clinical CAR-T lymphoma because its be poster of SPiReL on Annual many of promising, honor large Novel medical is cells cannot this study, and not to illnesses comorbid As during presented the it shows are medical is being present these control because but to Slide and approaches are toxicity patients. patients of this I'm SITC this which relapsed and required that need. of you the week that the investigator Meeting. starting
that have we and administered seven novel a checkpoint please. have X.X and in three combination inhibitors obtained for lymphoma every that diffuse off immune been days Single-agent limited therapy relapsed inhibitor XXX on dose intermittent milligrams Study daily includes DPX-Survivac, tested subcutaneous as Pembrolizumab immune antibody XX seven survivin activity on the refractory intermittent weeks, cyclophosphamide, X.X monoclonal doses received approved treatment activating novel once every and tumor-associated dose T-cells. weeks. inhibitor days treatment. against humanized regulatory generates have cyclophosphamide, PD-X of not a metronomic, twice antigen, targeted the then low binding immune population. and modulator. slide, an T-cell large pembrolizumab, B-cell then checkpoint Next also to responses a biopsies And includes DPX-Survivac, doses of low administering milligrams weeks were was pretreatment at ml doses intravenously and Subjects apart, three an tumor eight ml therapy
and large the expression Subjects B-cell XX%. survivin the lymphoma refractory treatment or participation please. patients eligible relapsed criteria cheson objective combination primary using minimum and with slide, modified response a The looking with incurable in or XX for to rate of are response X study. is rate document for the diffuse Next endpoint objective for
XX transformed described XX included objectives and XX autologous patient previous T-cell two identification. tumor, a first is subjects previous median this are date, refractory, transplant. biomarker exploratory in The characteristics population and have treatments Secondary enrolled the infiltration cell of poster. endpoints and have of immune four or disease, table. seven had cell enrolled, been response, shown had stem they the and in this Six To
Next slide, please.
been and has valuable primary information subjects assessment. XX And whom of have have presentation. the of now been endpoint. with are per-protocol of have the completed three data having doses cut enrolled. its of abstract, have that upon so subjects first complete and based this As study analysis the SPiReL response. criteria, an reached off, included of on-treatment received biomarker achieved Pembroluzimab, doses for having them response, this with XX four with four seven patients partial in DPX-Survivac, complete imaging a a objective we three the response, The XX
clinical one quickly stable infiltrates adverse biomarkers evaluated majority respond to grade that In protocol. we of other observe site related subjects two all have most minimal to events disease. and most three addition, therapy. and achieved this with patients DPX-Survivac. are who with immune subjects were We likely disease grade to not immune In identify injection of novel diverse toxicity progressive demonstrated the Whereas potentially progressed non-responders and to available benefits, for
Next slide, please.
shown different the have see with positive clinical PD-LX biopsies cell shown clinical their analysis can or photomicrographs upon clear the baseline the complete the patients subjects performed regulatory with sample partial having bar response the CD-X We CD-X various cells, we in lymphoma of shown or expression and the the The baseline PD-LX actual a tumor a and show baseline of responses tumor of XX bars response magenta lines. red In IHC cells dashed categorized analysis. graph, bar cells, in figure, below we graph. FOXPX multiplex the subtypes XX the in vertical of of observation available of and expression of positive here demonstrates a subjects bar of Below the graph cells, for PD-LX slides. presence immune infiltrates, left based response, increased status the variation with pink positive
left seen compared of had PD-LX all who progressive had intensity expression patient to or response disease. three clinical greater which on in on samples see benefit the can than absent PD-LX the treatment of the right, expression the You the from the
Next on predictive of the for Figure complete analysis, demonstrated clinical are cut possible PD-LX achieved greater results making so there analyzed a a PD-LX on PD-LX combination expressed response and is multiplex slide, IHC Shown partial tumor assessed and B, please. on microenvironment, study B-cells, subjects cells IHC and expression PD-LX baseline this XX% CDXX a immune expression by using statistically are than Figures significant and response here. all All D. using A in and C between therapy. PD-LX a documented Interestingly, multiplex importantly, or off correlation response who as response
PD-LX positive response. greater You can a percent cells with that cells percent patients in see positive is clinical significantly PD-LX in total or
slide, Next please.
baseline also in best response. compared on specific significant a statistically demonstrated treatment increase with We the responses survivin when have T-cell to response
response, DPX-Survivac in action subjects XXX% specific XX% of a induced a DPX-Survivac. of with survivin mechanism in partial responses in highlighted are subjects panel the supporting complete of of T-cell As B, with observed response
action. and specific The as and disease of baseline induction induced and with associated expression I'd support and like of The response novel in predictor survivin a refractory induced B-cell conclusion, slide, survivin Next of DPX-Survivac, in with and your novel now diffuse tumors immunotherapy Joanne. and control a attention are and PD-LX patients interactive dose turn please. Clinical lymphoma. expression higher PD-LX you combination T-cell association on lymphoma. relapsed thank between DPX-Survivac the responses the combination specific of cyclophosphamide large responses. large diffuse a refractory in potential immunotherapy In PD-LX T-cell and B-cell suggest B-cells Pembrolizumab clinical to with higher for low call to expression this immune response relapsed of to important PD-LX mechanism responses over baseline
